SkinBioTherapeutics Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BF33H870
GBP
0.06
-0.12 (-66.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Poor long term growth as Operating profit has grown by an annual rate 5.53% of over the last 5 years

 
3

With a growth in Net Sales of 94.2%, the company declared Very Positive results in Jun 25

4

Risky -

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 25 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.43

stock-summary
Return on Equity

-12.70%

stock-summary
Price to Book

2.64

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-69.51%
0%
-69.51%
6 Months
-60.94%
0%
-60.94%
1 Year
-35.96%
0%
-35.96%
2 Years
-52.83%
0%
-52.83%
3 Years
-71.26%
0%
-71.26%
4 Years
-90.67%
0%
-90.67%
5 Years
-54.84%
0%
-54.84%

SkinBioTherapeutics Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
41.34%
EBIT Growth (5y)
5.53%
EBIT to Interest (avg)
-2.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.19
Tax Ratio
0.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.95
EV to EBIT
-21.16
EV to EBITDA
-23.77
EV to Capital Employed
4.44
EV to Sales
5.12
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-20.99%
ROE (Latest)
-12.70%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by SkinBioTherapeutics Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 283.33% vs 1,100.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 75.86% vs -3.57% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.60",
          "val2": "1.20",
          "chgp": "283.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-2.40",
          "chgp": "83.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "-0.30",
          "chgp": "166.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-2.90",
          "chgp": "75.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-178.30%",
          "val2": "-2,133.30%",
          "chgp": "195.50%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Jun'25stock-summary

Jun'25
Jun'24
Change(%)
Net Sales
4.60
1.20
283.33%
Operating Profit (PBDIT) excl Other Income
-0.40
-2.40
83.33%
Interest
0.10
0.10
Exceptional Items
0.20
-0.30
166.67%
Consolidate Net Profit
-0.70
-2.90
75.86%
Operating Profit Margin (Excl OI)
-178.30%
-2,133.30%
195.50%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is 283.33% vs 1,100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 75.86% vs -3.57% in Jun 2024

stock-summaryCompany CV
About SkinBioTherapeutics Plc stock-summary
stock-summary
SkinBioTherapeutics Plc
Pharmaceuticals & Biotechnology
SkinBioTherapeutics PLC is a life science company focused on skin health. The Company’s platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company’s SkinBiotix platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. It focuses on three specific skin healthcare sectors: cosmetics, infection control and eczema. In each of these areas, the Company plans to exemplify its technology in human studies. The Company’s program is focused on the application of the Skinbiotix platform in managing sensitive skin in the cosmetics industry. SkinBiotix increases the rate of skin healing in response to injury.
Company Coordinates stock-summary
Company Details
15 1 Silk House, Park Green , MACCLESFIELD None : SK11 7QJ
Registrar Details